World Allergy Organization Journal最新文献

英文中文

Rethinking Inhaled Allergen Testing: A Cost-Effective and Evidence-Based Approach in Immunology Laboratories 重新思考吸入过敏原测试：在免疫学实验室的成本效益和循证方法

IF 4.3 2区医学 Q2 ALLERGY

World Allergy Organization Journal

Pub Date : 2026-02-01 Epub Date: 2026-03-05 DOI: 10.1016/j.waojou.2026.101329

Raja Abdulhadi , Abeer Qush , Hana’a Ramadan , Khadija Biaz , Buthaina Shaheen , Atefah Pour , Renan Awni , Sherlene Barrientos , Foziyeh Naji , Maryam Ali Al-Nesf , Medhat Askar , Firyal Ibrahim , Aziz A. Chentoufi

引用次数: 0

Experience of a specialized drug allergy clinic: challenges and opportunities in managing multiple drug allergy 专业药物过敏门诊的经验：管理多种药物过敏的挑战和机遇

IF 4.3 2区医学 Q2 ALLERGY

World Allergy Organization Journal

Pub Date : 2026-02-01 Epub Date: 2026-03-05 DOI: 10.1016/j.waojou.2026.101266

Salma A. Taha , Wisam Alwassiti , Asaad Imameldin , Soosan Samuel , Sibi Shibu , Hassan Mobayed , Maryam Ali Al-Nesf

引用次数: 0

Epidemiology and molecular study of IgE mediated food allergy in South Tunisian children 南突尼斯儿童IgE介导的食物过敏流行病学及分子研究

IF 4.3 2区医学 Q2 ALLERGY

World Allergy Organization Journal

Pub Date : 2026-02-01 Epub Date: 2026-03-05 DOI: 10.1016/j.waojou.2026.101271

A. Jerbi , S. Feki , S. Ben Ameur , T. Kammoun , H. Hachicha

引用次数: 0

From Despair to Remission: Successful Treatment of Eosinophilic Esophagitis with Dupiluamb: Two Case Reports from Qatar 从绝望到缓解：Dupiluamb成功治疗嗜酸性食管炎：来自卡塔尔的两例报告

IF 4.3 2区医学 Q2 ALLERGY

World Allergy Organization Journal

Pub Date : 2026-02-01 Epub Date: 2026-03-05 DOI: 10.1016/j.waojou.2026.101311

Mohamed Elhadi , Sami Aqil , Asaad Imameldin , Abulgasim Mohamed Ennkaa , Maryam Ali Al-Nesf , Hassan Mobayed , Tayseer Ibrahim

引用次数: 0

Where the Wind Carries Pollen and Fungus: Aerobiological Monitoring Sites in Qatar 风把花粉和真菌带到哪里：卡塔尔的有氧生物监测点

IF 4.3 2区医学 Q2 ALLERGY

World Allergy Organization Journal

Pub Date : 2026-02-01 Epub Date: 2026-03-05 DOI: 10.1016/j.waojou.2026.101309

Yasmin M. ElKhatib , Asmaa Abdelqaier , Sami Aqel , Maria Del Mar Trigo , Maryam Ali Y Al-Nesf

引用次数: 0

Title page 标题页

IF 4.3 2区医学 Q2 ALLERGY

World Allergy Organization Journal

Pub Date : 2026-02-01 Epub Date: 2026-03-05 DOI: 10.1016/S1939-4551(26)00188-2

引用次数: 0

A familial form of Atypical Hemolytic Uremic Syndrome associated with CD46 deficiency 与CD46缺乏相关的非典型溶血性尿毒症综合征的家族型

IF 4.3 2区医学 Q2 ALLERGY

World Allergy Organization Journal

Pub Date : 2026-02-01 Epub Date: 2026-03-05 DOI: 10.1016/j.waojou.2026.101275

Sihem Taguemount , Azzeddine Tahiat , Nadia Chaouchi , Kamel Djenouhat

引用次数: 0

Prevalence and risk factors of papular urticaria among school children in Cartagena, Colombia 哥伦比亚卡塔赫纳学龄儿童流行性荨麻疹患病率及危险因素

IF 4.3 2区医学 Q2 ALLERGY

World Allergy Organization Journal

Pub Date : 2026-02-01 Epub Date: 2026-01-13 DOI: 10.1016/j.waojou.2025.101151

Josefina Zakzuk MD, PhD , Juliana Quintero MD, PhD , Devian Parra Eco , Victoria Marrugo MSc , Maria A. Forero Molina MD , Carlos Quiroz MD , Margarita Ochoa-Díaz MD, Esp., MSc, PhD , Doris Gómez MSc, PhD , Elizabeth García MD

Introduction

Papular urticaria (PU) is a chronic allergic reaction to arthropod bites and is a common cause of pediatric dermatologic consultations in tropical regions. This study aimed to assess the prevalence and associated factors of PU among children in Cartagena, Colombia, and to explore the relationship between insect presence and disease presentation.

Methods

Surveys were used to assess living conditions, and the diagnosis was confirmed by medical history and physical examination.

Results

A total of 725 children aged 1–6 years from 30 schools and 13 childcare centers were included, PU was diagnosed in 260 children, resulting in an age- and gender-adjusted prevalence rate of 35.9% (95% CI: 30.3–43.4). Lesions were primarily found on exposed areas, such as the lower limbs (97%) and arms (54%). Children aged 1–2 years (aOR = 3.01, 95% CI: 1.54–5.93, p < 0.001) and 3–4 years (aOR = 1.84, 95% CI: 1.11–3.08, p = 0.02) had a higher risk of PU than those aged 5–6 years. The antecedent of mosquito bites was reported in most PU cases (96.0%) and controls (93.0%), without significant differences between groups. The frequency of mosquito presence at home was similar between case and controls. Mosquito density was higher in the lower socioeconomic strata (p < 0.001). The most commonly identified species were Aedes aegypti (57.7%) and Culex quinquefasciatus (38.2%). Fleas were found in only 3% of the homes.

Conclusion

We identified a high prevalence of PU in the city. Despite the widespread presence of mosquitoes, no association between mosquito bites and PU was observed. Younger age emerged as a risk factor for PU, and socioeconomic disparities influenced higher mosquito density.

丘疹性荨麻疹（PU）是一种对节肢动物叮咬的慢性过敏反应，是热带地区儿童皮肤科会诊的常见原因。本研究旨在评估哥伦比亚卡塔赫纳地区儿童PU患病率及其相关因素，并探讨昆虫存在与疾病表现之间的关系。方法采用问卷调查的方式评估患者的生活状况，并结合病史和体格检查进行诊断。结果共纳入30所学校和13所托幼中心的1 ~ 6岁儿童725名，诊断为PU的儿童260名，经年龄和性别调整的患病率为35.9% （95% CI: 30.3 ~ 43.4）。病变主要发生在暴露部位，如下肢（97%）和手臂（54%）。1 ~ 2岁儿童（aOR = 3.01, 95% CI: 1.54 ~ 5.93, p < 0.001）和3 ~ 4岁儿童（aOR = 1.84, 95% CI: 1.11 ~ 3.08, p = 0.02）发生PU的风险高于5 ~ 6岁儿童。大多数PU病例（96.0%）和对照组（93.0%）报告有蚊虫叮咬史，组间差异无统计学意义。在病例和对照之间，蚊虫在家中出现的频率相似。低社会经济阶层的蚊密度较高（p < 0.001）。最常见的蚊种为埃及伊蚊（57.7%）和致倦库蚊（38.2%）。只有3%的家庭有跳蚤。结论我市PU患病率较高。尽管蚊子广泛存在，但没有观察到蚊子叮咬与PU之间的联系。年龄较小是PU的危险因素，社会经济差异影响了较高的蚊子密度。

{"title":"Prevalence and risk factors of papular urticaria among school children in Cartagena, Colombia","authors":"Josefina Zakzuk MD, PhD , Juliana Quintero MD, PhD , Devian Parra Eco , Victoria Marrugo MSc , Maria A. Forero Molina MD , Carlos Quiroz MD , Margarita Ochoa-Díaz MD, Esp., MSc, PhD , Doris Gómez MSc, PhD , Elizabeth García MD","doi":"10.1016/j.waojou.2025.101151","DOIUrl":"10.1016/j.waojou.2025.101151","url":null,"abstract":"<div><h3>Introduction</h3><div>Papular urticaria (PU) is a chronic allergic reaction to arthropod bites and is a common cause of pediatric dermatologic consultations in tropical regions. This study aimed to assess the prevalence and associated factors of PU among children in Cartagena, Colombia, and to explore the relationship between insect presence and disease presentation.</div></div><div><h3>Methods</h3><div>Surveys were used to assess living conditions, and the diagnosis was confirmed by medical history and physical examination.</div></div><div><h3>Results</h3><div>A total of 725 children aged 1–6 years from 30 schools and 13 childcare centers were included, PU was diagnosed in 260 children, resulting in an age- and gender-adjusted prevalence rate of 35.9% (95% CI: 30.3–43.4). Lesions were primarily found on exposed areas, such as the lower limbs (97%) and arms (54%). Children aged 1–2 years (aOR = 3.01, 95% CI: 1.54–5.93, p < 0.001) and 3–4 years (aOR = 1.84, 95% CI: 1.11–3.08, p = 0.02) had a higher risk of PU than those aged 5–6 years. The antecedent of mosquito bites was reported in most PU cases (96.0%) and controls (93.0%), without significant differences between groups. The frequency of mosquito presence at home was similar between case and controls. Mosquito density was higher in the lower socioeconomic strata (p < 0.001). The most commonly identified species were <em>Aedes aegypti</em> (57.7%) and <em>Culex quinquefasciatus</em> (38.2%). Fleas were found in only 3% of the homes.</div></div><div><h3>Conclusion</h3><div>We identified a high prevalence of PU in the city. Despite the widespread presence of mosquitoes, no association between mosquito bites and PU was observed. Younger age emerged as a risk factor for PU, and socioeconomic disparities influenced higher mosquito density.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"19 2","pages":"Article 101151"},"PeriodicalIF":4.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145957885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Developing a patient journey map to improve care and experience in Chinese patients with hereditary angioedema 制定患者旅程图以改善中国遗传性血管性水肿患者的护理和经验

IF 4.3 2区医学 Q2 ALLERGY

World Allergy Organization Journal

Pub Date : 2026-02-01 Epub Date: 2026-01-30 DOI: 10.1016/j.waojou.2026.101333

Yin Wang MM , Yangxue Fu PhD , Hao Chen PhD , Jin Liu MD , Qingxiu Xu MD , Yaqi Yang MD , Si Zhang BS , Jing Cheng MD , Rongfei Zhu MD, PhD

Background

Hereditary angioedema (HAE) is a rare disorder that imposes a substantial burden on patient health and quality of life. Although international studies have highlighted specific aspects of the HAE care continuum, comprehensive evidence on patient experiences in China remains scarce.

Methods

We conducted a single-center, mixed-methods study to develop the first HAE Patient Journey Map (HAE-PJM) in China. Fifteen adult patients with HAE were recruited for structured interviews (July–November 2024), complemented by quantitative assessments using the Hospital Anxiety and Depression Scale (HADS) and the Angioedema Control Test (AECT). Stakeholder validation was obtained through expert–patient groups.

Results

Patients experienced a mean diagnostic delay of 16.3 years, with 80% reporting misdiagnosis and high rates of inappropriate interventions, underscoring systemic deficiencies in early recognition. Pre-diagnosis, activity limitations, and anxiety were common; genetic and economic anxieties persisted even after treatment initiation despite improvements in HADS and AECT scores. Prophylactic regimens achieved superior disease control compared with on-demand therapy, yet access barriers—including cost, reimbursement, and drug availability—remained prevalent. Expert-patient group validation confirmed the relevance of a phased patient journey map and emphasized multidisciplinary roles, including physicians, nurses, navigators, and societal support systems.

Conclusion

This study provides the first systematic HAE-PJM in China, integrating qualitative and quantitative evidence to delineate critical touchpoints and bottlenecks in HAE care. To address these identified challenges, we propose a “4T″ framework (Testing, Teaching, Therapeutic Monitoring, and Team working). These findings highlight urgent needs for standardized diagnostic pathways, integrated psychosocial and financial support, and access-oriented care models.

背景：遗传性血管性水肿（HAE）是一种罕见的疾病，对患者的健康和生活质量造成了严重的负担。尽管国际研究强调了HAE治疗连续性的具体方面，但关于中国患者经历的综合证据仍然很少。方法：我们开展了一项单中心、混合方法研究，在中国开发首个HAE患者旅程地图（HAE- pjm）。我们招募了15名患有HAE的成年患者进行结构化访谈（2024年7月至11月），并辅以使用医院焦虑和抑郁量表（HADS）和血管性水肿控制测试（AECT）进行定量评估。通过专家-患者分组获得利益相关者验证。结果患者平均诊断延迟16.3年，80%报告误诊，干预不当率高，突出了早期识别的系统性缺陷。诊断前、活动受限和焦虑是常见的；即使在治疗开始后，尽管HADS和AECT评分有所改善，遗传和经济焦虑仍然存在。与按需治疗相比，预防性治疗方案取得了更好的疾病控制效果，但获取障碍——包括成本、报销和药物可得性——仍然普遍存在。专家-患者组验证确认了分阶段患者旅程图的相关性，并强调了多学科作用，包括医生、护士、导航员和社会支持系统。本研究提供了中国第一个系统的HAE- pjm，整合了定性和定量证据来描述HAE护理的关键接触点和瓶颈。为了解决这些已确定的挑战，我们提出了“4T″框架（测试，教学，治疗监测和团队合作）”。这些发现突出表明，迫切需要标准化的诊断途径、综合的社会心理和经济支持以及面向可及性的护理模式。

{"title":"Developing a patient journey map to improve care and experience in Chinese patients with hereditary angioedema","authors":"Yin Wang MM , Yangxue Fu PhD , Hao Chen PhD , Jin Liu MD , Qingxiu Xu MD , Yaqi Yang MD , Si Zhang BS , Jing Cheng MD , Rongfei Zhu MD, PhD","doi":"10.1016/j.waojou.2026.101333","DOIUrl":"10.1016/j.waojou.2026.101333","url":null,"abstract":"<div><h3>Background</h3><div>Hereditary angioedema (HAE) is a rare disorder that imposes a substantial burden on patient health and quality of life. Although international studies have highlighted specific aspects of the HAE care continuum, comprehensive evidence on patient experiences in China remains scarce.</div></div><div><h3>Methods</h3><div>We conducted a single-center, mixed-methods study to develop the first HAE Patient Journey Map (HAE-PJM) in China. Fifteen adult patients with HAE were recruited for structured interviews (July–November 2024), complemented by quantitative assessments using the Hospital Anxiety and Depression Scale (HADS) and the Angioedema Control Test (AECT). Stakeholder validation was obtained through expert–patient groups.</div></div><div><h3>Results</h3><div>Patients experienced a mean diagnostic delay of 16.3 years, with 80% reporting misdiagnosis and high rates of inappropriate interventions, underscoring systemic deficiencies in early recognition. Pre-diagnosis, activity limitations, and anxiety were common; genetic and economic anxieties persisted even after treatment initiation despite improvements in HADS and AECT scores. Prophylactic regimens achieved superior disease control compared with on-demand therapy, yet access barriers—including cost, reimbursement, and drug availability—remained prevalent. Expert-patient group validation confirmed the relevance of a phased patient journey map and emphasized multidisciplinary roles, including physicians, nurses, navigators, and societal support systems.</div></div><div><h3>Conclusion</h3><div>This study provides the first systematic HAE-PJM in China, integrating qualitative and quantitative evidence to delineate critical touchpoints and bottlenecks in HAE care. To address these identified challenges, we propose a “4T″ framework (Testing, Teaching, Therapeutic Monitoring, and Team working). These findings highlight urgent needs for standardized diagnostic pathways, integrated psychosocial and financial support, and access-oriented care models.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"19 2","pages":"Article 101333"},"PeriodicalIF":4.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146079420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Dupilumab in real-world pediatric asthma: Enhanced control and quality of life for children and caregivers Dupilumab在现实儿科哮喘中的应用：增强儿童和护理人员的控制和生活质量

IF 4.3 2区医学 Q2 ALLERGY

World Allergy Organization Journal

Pub Date : 2026-02-01 Epub Date: 2026-01-18 DOI: 10.1016/j.waojou.2026.101251

Ricardo Martínez-Tenopala MD , Jimena Prieto-Gomez MD , María Julia Rendón-Salazar MD , Tamara Hernández-Hernández MD , Javier Zermeño-Vallet MD , Diego Mauricio Gómez-González MD , Carlos Andrés Gómez-Nuñez MD , Luis Ángel Hernández-Zárate MD , Víctor Gonzalez-Uribe MD, MSc

Background

Dupilumab has demonstrated therapeutic benefits and improved quality of life (QoL) in children with uncontrolled asthma. This real-world study—the first in a Latin-American pediatric population—evaluated its impact on asthma control and QoL in children with moderate-to-severe uncontrolled type 2 asthma and their caregivers.

Methods

We conducted a retrospective observational study of patients aged 4–16 years with moderate-to-severe uncontrolled type 2 asthma (blood eosinophils ≥150 cells/μL or fractional exhaled nitric oxide ≥20 ppb). Eleven patients received dupilumab and 12 received conventional inhaled therapy, with 52-week follow-up. Asthma control was assessed using the 7-item Asthma Control Questionnaire interviewer-administered version (ACQ-7-IA). QoL was evaluated using the Pediatric Asthma Quality of Life Questionnaire interviewer-administered version (PAQLQ[S]-IA) and the Pediatric Asthma Caregiver's Quality of Life Questionnaire (PACQLQ). The primary endpoints were changes in ACQ-7-IA, PAQLQ(S)-IA, and PACQLQ scores, and the proportion achieving clinically significant improvement (≥0.5 points).

Results

Dupilumab significantly improved ACQ-7-IA scores from week 4, sustained through week 52 (least squares mean difference −0.44, 95% CI −0.59 to −0.30; p < 0.001). At week 52, 86% of dupilumab-treated patients achieved clinically significant improvement versus 75% with conventional therapy (p = 0.041). Well-controlled asthma (ACQ-7-IA ≤0.75) was achieved in 73% versus 36% (p < 0.003). Dupilumab also improved PAQLQ(S)-IA and PACQLQ scores from week 24, with 100% of patients and caregivers achieving clinically significant improvement at week 52.

Conclusions

In Latin-American children with moderate-to-severe type 2 asthma, dupilumab was associated with early and sustained improvements in asthma control and QoL for both patients and caregivers, supporting its role as an effective therapeutic option in real-world pediatric practice.

研究背景：dupilumab已经证明了治疗哮喘患儿的益处和改善生活质量（QoL）。这项真实世界的研究-首次在拉丁美洲儿科人群中进行-评估了其对中度至重度未控制的2型哮喘儿童及其护理人员的哮喘控制和生活质量的影响。方法对4-16岁中重度未控制的2型哮喘患者（血嗜酸性粒细胞≥150细胞/μL或呼气一氧化氮≥20 ppb）进行回顾性观察研究。11例患者接受dupilumab治疗，12例接受常规吸入治疗，随访52周。哮喘控制采用7项哮喘控制问卷（ACQ-7-IA）进行评估。生活质量采用儿童哮喘生活质量问卷（PAQLQ[S]-IA）和儿童哮喘护理人员生活质量问卷（PACQLQ）进行评估。主要终点为ACQ-7-IA、PAQLQ(S)-IA和PACQLQ评分的变化，以及达到临床显著改善（≥0.5分）的比例。结果dupilumab从第4周开始显著改善ACQ-7-IA评分，持续到第52周（最小二乘平均差为- 0.44,95% CI为- 0.59至- 0.30;p < 0.001）。在第52周，86%的dupilumab治疗患者获得临床显著改善，而75%的常规治疗患者（p = 0.041）。哮喘（ACQ-7-IA≤0.75）得到良好控制的比例分别为73%和36% （p < 0.003）。从第24周开始，Dupilumab也改善了PAQLQ(S)-IA和PACQLQ评分，100%的患者和护理人员在第52周达到临床显着改善。结论：在拉丁美洲患有中重度2型哮喘的儿童中，dupilumab与患者和护理人员的哮喘控制和生活质量的早期和持续改善相关，支持其作为现实世界儿科实践中有效的治疗选择的作用。

{"title":"Dupilumab in real-world pediatric asthma: Enhanced control and quality of life for children and caregivers","authors":"Ricardo Martínez-Tenopala MD , Jimena Prieto-Gomez MD , María Julia Rendón-Salazar MD , Tamara Hernández-Hernández MD , Javier Zermeño-Vallet MD , Diego Mauricio Gómez-González MD , Carlos Andrés Gómez-Nuñez MD , Luis Ángel Hernández-Zárate MD , Víctor Gonzalez-Uribe MD, MSc","doi":"10.1016/j.waojou.2026.101251","DOIUrl":"10.1016/j.waojou.2026.101251","url":null,"abstract":"<div><h3>Background</h3><div>Dupilumab has demonstrated therapeutic benefits and improved quality of life (QoL) in children with uncontrolled asthma. This real-world study—the first in a Latin-American pediatric population—evaluated its impact on asthma control and QoL in children with moderate-to-severe uncontrolled type 2 asthma and their caregivers.</div></div><div><h3>Methods</h3><div>We conducted a retrospective observational study of patients aged 4–16 years with moderate-to-severe uncontrolled type 2 asthma (blood eosinophils ≥150 cells/μL or fractional exhaled nitric oxide ≥20 ppb). Eleven patients received dupilumab and 12 received conventional inhaled therapy, with 52-week follow-up. Asthma control was assessed using the 7-item Asthma Control Questionnaire interviewer-administered version (ACQ-7-IA). QoL was evaluated using the Pediatric Asthma Quality of Life Questionnaire interviewer-administered version (PAQLQ[S]-IA) and the Pediatric Asthma Caregiver's Quality of Life Questionnaire (PACQLQ). The primary endpoints were changes in ACQ-7-IA, PAQLQ(S)-IA, and PACQLQ scores, and the proportion achieving clinically significant improvement (≥0.5 points).</div></div><div><h3>Results</h3><div>Dupilumab significantly improved ACQ-7-IA scores from week 4, sustained through week 52 (least squares mean difference −0.44, 95% CI −0.59 to −0.30; p < 0.001). At week 52, 86% of dupilumab-treated patients achieved clinically significant improvement versus 75% with conventional therapy (p = 0.041). Well-controlled asthma (ACQ-7-IA ≤0.75) was achieved in 73% versus 36% (p < 0.003). Dupilumab also improved PAQLQ(S)-IA and PACQLQ scores from week 24, with 100% of patients and caregivers achieving clinically significant improvement at week 52.</div></div><div><h3>Conclusions</h3><div>In Latin-American children with moderate-to-severe type 2 asthma, dupilumab was associated with early and sustained improvements in asthma control and QoL for both patients and caregivers, supporting its role as an effective therapeutic option in real-world pediatric practice.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"19 2","pages":"Article 101251"},"PeriodicalIF":4.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146039141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

World Allergy Organization Journal

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀